{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T04:44:00Z","timestamp":1795149840041,"version":"4.10.3"},"reference-count":17,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Scleromyxedema, the most severe manifestation of the spectrum of lichen myxedematosus, is characterized by cutaneous mucinosis, extracutaneous manifestations, and a monoclonal gammopathy. Seven of 8 patients evaluated at our center were treated with high-dose melphalan (180 mg\/m2 intravenously) and autologous peripheral blood stem cell transplantation, with marked improvement of gastrointestinal, central nervous system, pulmonary manifestations, and Karnofsky performance status. Five patients obtained a cutaneous complete remission and 2 patients had partial remissions. Three patients with slight progression in the skin at 12, 8, and 4 months after treatment received a second cycle of high-dose melphalan and had further symptomatic improvement. The lichen myxedematosus\u2013scleromyxedema spectrum appears to be a continuum that requires the presence of a serum paraprotein and differs in severity of skin lesions, extracutaneous manifestations, and performance status. High-dose melphalan followed by autologous transplantation appears effective for improving the symptoms and systemic manifestations of scleromyxedema.<\/jats:p>","DOI":"10.1182\/blood-2004-12-4870","type":"journal-article","created":{"date-parts":[[2005,9,22]],"date-time":"2005-09-22T20:13:31Z","timestamp":1127420011000},"page":"463-466","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":58,"title":["Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation"],"prefix":"10.1182","volume":"107","author":[{"given":"Michele L.","family":"Donato","sequence":"first","affiliation":[{"name":"From the Departments of Blood and Bone Marrow Transplantation, Dermatology, Myeloma, and Dermatopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne M.","family":"Feasel","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Bone Marrow Transplantation, Dermatology, Myeloma, and Dermatopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Weber","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Bone Marrow Transplantation, Dermatology, Myeloma, and Dermatopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor G.","family":"Prieto","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Bone Marrow Transplantation, Dermatology, Myeloma, and Dermatopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Bone Marrow Transplantation, Dermatology, Myeloma, and Dermatopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Bone Marrow Transplantation, Dermatology, Myeloma, and Dermatopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[{"name":"From the Departments of Blood and Bone Marrow Transplantation, Dermatology, Myeloma, and Dermatopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111817285078400_REF1","doi-asserted-by":"crossref","unstructured":"Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001;44: 273-281.","DOI":"10.1067\/mjd.2001.111630"},{"key":"2019111817285078400_REF2","doi-asserted-by":"crossref","unstructured":"Rayson D, Lust JA, Duncan A, et al. Scleromyxedema: a complete response to prednisone. Mayo Clin Proc. 1999;74: 481-484.","DOI":"10.1016\/S0025-6196(11)65128-8"},{"key":"2019111817285078400_REF3","doi-asserted-by":"crossref","unstructured":"Lister RK, Jolles S, Whittaker S, et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol. 2000;43: 403-408.","DOI":"10.1067\/mjd.2000.104001"},{"key":"2019111817285078400_REF4","doi-asserted-by":"crossref","unstructured":"Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol. 1995;33: 37-43.","DOI":"10.1016\/0190-9622(95)90007-1"},{"key":"2019111817285078400_","unstructured":"Nieves DS, Bondi EE, Wallmark J, et al. Scleromyxedema: successful treatment of cutaneous and neurologic symptoms. Cutis. 2000;65: 89-92."},{"key":"2019111817285078400_REF6","doi-asserted-by":"crossref","unstructured":"Harris RB, Perry HD, Kyler RA, et al. Treatment of scleromyxedema with melphalan. Arch Dermatol. 1979;115: 295-299.","DOI":"10.1001\/archderm.1979.04010030003002"},{"key":"2019111817285078400_REF7","doi-asserted-by":"crossref","unstructured":"Peggs KS, Paneesha S, Kottaridis PD, et al. Peripheral blood stem cell transplantation for POEMS syndrome. Bone Marrow Transplantation. 2002;30: 401-404.","DOI":"10.1038\/sj.bmt.1703670"},{"key":"2019111817285078400_REF8","doi-asserted-by":"crossref","unstructured":"Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140: 85-93.","DOI":"10.7326\/0003-4819-140-2-200401200-00008"},{"key":"2019111817285078400_REF9","unstructured":"Feasel AM, Donato ML, Duvic M. Complete remission of scleromyxedema following autologous stem cell transplantation. Arch Dermatol. 2001;137: 1071-1072."},{"key":"2019111817285078400_REF10","unstructured":"Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLead CM, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949: 199-205."},{"key":"2019111817285078400_REF11","doi-asserted-by":"crossref","unstructured":"Montgomery H, Underwood LJ. Lichen myxedematosus: differentiation from cutaneous myxedemas or mucoid states. J Invest Dermatol. 1953;20: 213-236.","DOI":"10.1038\/jid.1953.25"},{"key":"2019111817285078400_REF12","doi-asserted-by":"crossref","unstructured":"Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48: 1437-1444.","DOI":"10.1093\/clinchem\/48.9.1437"},{"key":"2019111817285078400_REF13","doi-asserted-by":"crossref","unstructured":"Harper RA, Rispler J. Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science. 1978;199: 545-547.","DOI":"10.1126\/science.622555"},{"key":"2019111817285078400_REF14","unstructured":"Yaron M, Yaron I, Yust I, et al. Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol. 1985;12: 171-175."},{"key":"2019111817285078400_REF15","doi-asserted-by":"crossref","unstructured":"Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348: 1875-1883.","DOI":"10.1056\/NEJMoa022340"},{"key":"2019111817285078400_REF16","doi-asserted-by":"crossref","unstructured":"Finnish Leukemia Group. Acute leukemia and other secondary neoplasms in patients treated with conventional chemotherapy for Multiple Myeloma: a Finnish leukemia group study. Eur J Haematol. 2000;65: 123-137.","DOI":"10.1034\/j.1600-0609.2000.90218.x"},{"key":"2019111817285078400_REF17","doi-asserted-by":"crossref","unstructured":"Harrison CN, Gregory W, Hudson GV, et al. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS\/AML. Br J Cancer. 1999;81: 476-483.","DOI":"10.1038\/sj.bjc.6690718"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/2\/463\/1280177\/zh800206000463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/2\/463\/1280177\/zh800206000463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T17:05:20Z","timestamp":1586451920000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/2\/463\/131445\/Scleromyxedema-role-of-highdose-melphalan-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,15]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,1,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-12-4870","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,15]]}}}